Trials / Recruiting
RecruitingNCT06323213
Efficacy and Safety Study of 610 in Patients With Severe Asthma
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of 610 in Chinese Adult Subjects With Severe Eosinophilic Asthma
- Status
- Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 480 (estimated)
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of the study is to evaluate the efficacy and safety of 610 in Chinese adults with severe asthma.
Detailed description
The total duration of study per patient is approximately 66 weeks, including 6 weeks of screening period, 52 weeks of treatment period and 8 weeks of follow-up period.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 610 | 610 subcutaneously injection. |
| DRUG | Placebo | Placebo subcutaneously injection. |
Timeline
- Start date
- 2024-06-24
- Primary completion
- 2027-02-01
- Completion
- 2027-09-01
- First posted
- 2024-03-21
- Last updated
- 2026-01-07
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06323213. Inclusion in this directory is not an endorsement.